LysgaardStensgaard12 blog
Subtitle
Blog
Biotebal rezultaty stosowania
|
|
Alopecia areata (al-uh-PEE-shuh air-ee-AH-tuh) is a condition that causes hair loss on the scalp and sometimes in other places on the body. Alopecia areata affects 0. 1-0. 2% of the population at any 1 time and has a lifetime risk of 1. 7%. 60% of individuals experience their first episode under the age of 20. Patients usually present with an abrupt episode of hair loss frequently in round or oval patches involving not just the scalp hair nevertheless any hair bearing region such as the beard, chest, axilla or hands. The hairs frequently break and expand at fractured ends resulting in a shape described as exclamation mark hairs”. Sometimes the whole scalp or even the whole body hair may be lost resulting in a pattern known because alopecia totalis or alopoecia universalis respectively.
Minoxidil (Rogaine, common versions). This drug was introduced as a treatment for high blood pressure, but people who took it discovered that they were growing hair in places wherever they had lost that. Research confirmed that the 2% solution of minoxidil utilized directly to the scalp could stimulate hair development. How it works is still not clear. Two double-blind studies of females ages 18 to forty five demonstrated its effectiveness. In one study, 13% of female minoxidil users got moderate hair regrowth, and 50%, minimal growth (compared with 6% and 33%, correspondingly, in the placebo group). In the second research, 60% of women in the minoxidil group reported new growth of hair, compared with 40% in the placebo group. As a result of these studies and others, over-the-counter 2% minoxidil is FDA-approved for treating androgenetic alopecia in women.
The exact reason of alopeciareata is not known. An autoimmune mechanism is suspected through this disorder. Autoimmune disorders will be caused when the body's natural defenses against foreign” or invading organisms (e. g., antibodies) begin to attack healthy tissue intended for unknown reasons. Some situations may be linked to abnormal reactions by simply blood cells (serum antibodies) to a thyroid protein (thyroglobulin), stomach (parietal) cells, or adrenal cells.
Alopecia is a basic term for hair reduction. Alopecia areata is a specific, common cause of hair loss that can easily occur at any age. It usually causes small, coin-sized, round patches of baldness on the scalp, though hair elsewhere such since the beard, eyebrows, eyelashes, body and limbs could be affected. Occasionally it can certainly involve the whole head (alopecia totalis) or even the entire body and scalp (alopecia universalis). It is not possible to predict how much curly hair will be lost. Regrowth of hair in common alopecia areata is normal over a period of months or sometimes years, but cannot end up being guaranteed. The hair sometimes regrows white, at least in the first instance. Further baldness is not uncommon. In alopecia totalis and calvicie universalis, the likelihood of total regrowth is much less.
Furthermore, an UpToDate review on Management of alopecia areata” (Messenger, 2017a) states that Topical preparations of ruxolitinib and tofacitinib have yielded promising results in mouse models of alopecia areata. In a patient with refractory peladera universalis, treatment with ruxolitinib 0. 6 % cream (twice-daily for 12 weeks) appeared to stimulate practically full eyebrow regrowth and approximately 10 % restoration of scalp hair. Of note, a small, steady decrease biotebal ulotka in the patient's white blood cell count took place during treatment. Additional study is important prior to results about the efficacy and safety of topical Janus kinase inhibitors for calvicie areata. Topical formulations of ruxolitinib and tofacitinib will be not commercially available”.
Minoxidil (Rogaine, common versions). This drug was introduced as a treatment for high blood pressure, but people who took it discovered that they were growing hair in places wherever they had lost that. Research confirmed that the 2% solution of minoxidil utilized directly to the scalp could stimulate hair development. How it works is still not clear. Two double-blind studies of females ages 18 to forty five demonstrated its effectiveness. In one study, 13% of female minoxidil users got moderate hair regrowth, and 50%, minimal growth (compared with 6% and 33%, correspondingly, in the placebo group). In the second research, 60% of women in the minoxidil group reported new growth of hair, compared with 40% in the placebo group. As a result of these studies and others, over-the-counter 2% minoxidil is FDA-approved for treating androgenetic alopecia in women.
The exact reason of alopeciareata is not known. An autoimmune mechanism is suspected through this disorder. Autoimmune disorders will be caused when the body's natural defenses against foreign” or invading organisms (e. g., antibodies) begin to attack healthy tissue intended for unknown reasons. Some situations may be linked to abnormal reactions by simply blood cells (serum antibodies) to a thyroid protein (thyroglobulin), stomach (parietal) cells, or adrenal cells.
Alopecia is a basic term for hair reduction. Alopecia areata is a specific, common cause of hair loss that can easily occur at any age. It usually causes small, coin-sized, round patches of baldness on the scalp, though hair elsewhere such since the beard, eyebrows, eyelashes, body and limbs could be affected. Occasionally it can certainly involve the whole head (alopecia totalis) or even the entire body and scalp (alopecia universalis). It is not possible to predict how much curly hair will be lost. Regrowth of hair in common alopecia areata is normal over a period of months or sometimes years, but cannot end up being guaranteed. The hair sometimes regrows white, at least in the first instance. Further baldness is not uncommon. In alopecia totalis and calvicie universalis, the likelihood of total regrowth is much less.
Furthermore, an UpToDate review on Management of alopecia areata” (Messenger, 2017a) states that Topical preparations of ruxolitinib and tofacitinib have yielded promising results in mouse models of alopecia areata. In a patient with refractory peladera universalis, treatment with ruxolitinib 0. 6 % cream (twice-daily for 12 weeks) appeared to stimulate practically full eyebrow regrowth and approximately 10 % restoration of scalp hair. Of note, a small, steady decrease biotebal ulotka in the patient's white blood cell count took place during treatment. Additional study is important prior to results about the efficacy and safety of topical Janus kinase inhibitors for calvicie areata. Topical formulations of ruxolitinib and tofacitinib will be not commercially available”.
Categories: None
Post a Comment
Oops!
The words you entered did not match the given text. Please try again.
Oops!
Oops, you forgot something.